Identification of patients at high risk of secondary extramedullary multiple myeloma development.
extramedullary disease
multiple myeloma
prognostic factors
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
17
08
2021
accepted:
14
10
2021
pubmed:
3
11
2021
medline:
3
3
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4·38, 95% confidence interval (CI): 2·46-7·80, P < 0·0001], high lactate dehydrogenase (LDH) levels (>5 μkat/l; OR 2·07, 95% CI: 1·51-2·84, P < 0·0001), extensive osteolytic activity (OR 2·21, 95% CI: 1·54-3·15, P < 0·001), and immunoglobulin A (IgA; OR 1·53, 95% CI: 1·11-2·11, P = 0·009) or the non-secretory type of MM (OR 2·83; 95% CI: 1·32-6·04, P = 0·007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13·8 months (95% CI: 11·4-16·3) vs 18·8 months (95% CI: 17·7-19·9), P = 0·006; mOS: 26·7 months (95% CI: 18·1-35·4) vs 58·7 months (95% CI: 54·8-62·6), P < 0·001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.
Identifiants
pubmed: 34726261
doi: 10.1111/bjh.17925
pmc: PMC9297924
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
954-962Informations de copyright
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Lancet. 2021 Jul 24;398(10297):314-324
pubmed: 34175021
Eur J Haematol. 2006 May;76(5):405-8
pubmed: 16529604
Blood. 2015 Mar 26;125(13):2095-100
pubmed: 25636340
PLoS One. 2015 Sep 21;10(9):e0137294
pubmed: 26389804
Br J Haematol. 2015 Jun;169(6):843-50
pubmed: 26032514
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Haematologica. 2020 Jan;105(1):193-200
pubmed: 31221778
Leukemia. 2011 Jun;25(6):906-8
pubmed: 21350560
Blood. 2012 Aug 2;120(5):1067-76
pubmed: 22498740
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
Leukemia. 2022 Jan;36(1):288-291
pubmed: 34247197
Lancet. 2017 Feb 4;389(10068):519-527
pubmed: 28017406
Eur J Haematol. 2016 Jul;97(1):93-100
pubmed: 26432667
BMC Cancer. 2021 Jan 15;21(1):73
pubmed: 33451293
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):286-91
pubmed: 25640025
Biol Blood Marrow Transplant. 2019 Nov;25(11):2134-2142
pubmed: 31288095
Blood. 2021 May 27;137(21):2890-2901
pubmed: 33512480
Ann Oncol. 2010 Feb;21(2):325-330
pubmed: 19633044
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Haematologica. 2012 Nov;97(11):1761-7
pubmed: 22689675
Haematologica. 2020 Jan;105(1):201-208
pubmed: 31278209
J Clin Oncol. 2018 Mar 10;36(8):728-734
pubmed: 29341834
Blood. 2016 Feb 25;127(8):971-6
pubmed: 26679866
Leukemia. 2015 Dec;29(12):2429-31
pubmed: 26442610
Cancer. 2012 Mar 15;118(6):1574-84
pubmed: 21932386
Am Soc Clin Oncol Educ Book. 2016;35:e418-23
pubmed: 27249749
Leukemia. 2020 Nov;34(11):2887-2897
pubmed: 32651540
Eur J Haematol. 2010 Apr;84(4):359-61
pubmed: 20002730
Haematologica. 2014 Feb;99(2):360-4
pubmed: 24038024
Blood Rev. 2019 Jul;36:32-39
pubmed: 31005420
Blood. 2016 May 26;127(21):2569-74
pubmed: 27002117
Lancet. 2019 Dec 7;394(10214):2096-2107
pubmed: 31735560
Haematologica. 2006 May;91(5):605-12
pubmed: 16627256
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
Br J Haematol. 2013 Apr;161(1):87-94
pubmed: 23368088
Cancers (Basel). 2020 Apr 23;12(4):
pubmed: 32340174
Blood. 2010 Nov 11;116(19):3724-34
pubmed: 20664057
Leukemia. 2009 Sep;23(9):1545-56
pubmed: 19421229
Nat Rev Clin Oncol. 2017 Aug;14(8):461-462
pubmed: 28607521
Front Immunol. 2021 Aug 05;12:720571
pubmed: 34421924
Eur J Haematol. 2019 May;102(5):389-394
pubmed: 30719772
Lancet Oncol. 2020 Feb;21(2):207-221
pubmed: 31859245
Blood. 2019 Feb 14;133(7):644-651
pubmed: 30587527
Clin Case Rep. 2017 Jun 22;5(8):1258-1260
pubmed: 28781837
N Engl J Med. 2018 Nov 8;379(19):1811-1822
pubmed: 30403938
Ann Hematol. 2017 Jan;96(1):73-80
pubmed: 27766391
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Blood. 2019 Aug 1;134(5):421-431
pubmed: 31113777
Klin Onkol. 2017 Summer;30(Supplementum2):35-42
pubmed: 28903569
Cancer. 2021 Nov 15;127(22):4198-4212
pubmed: 34314018
Lancet Oncol. 2019 Jun;20(6):781-794
pubmed: 31097405
Blood. 2011 Dec 1;118(23):5989-95
pubmed: 21900189
Lancet Haematol. 2020 May;7(5):e395-e407
pubmed: 32213344
J Clin Oncol. 2021 Jan 10;39(2):116-125
pubmed: 33151787